Google DeepMind's Isomorphic Labs Nears Human Trials for AI-Designed Drugs

Isomorphic Labs Prepares for Groundbreaking Human Trials

Isomorphic Labs, a subsidiary of Alphabet's Google DeepMind, is on the brink of a significant milestone in the field of AI-powered drug discovery. Colin Murdoch, President of Isomorphic Labs and Chief Business Officer of Google DeepMind, has announced that the company is "getting very close" to initiating human clinical trials for drugs designed using artificial intelligence 1

1

Source: Fortune

The Journey from AlphaFold to Human Trials

Isomorphic Labs was spun out of DeepMind in 2021, building upon the success of AlphaFold, an AI system capable of predicting protein structures with high accuracy. The evolution of AlphaFold has been crucial in advancing drug discovery capabilities:

1. Initially predicting individual protein structures
2. Progressing to modeling protein interactions with other molecules like DNA and drugs
3. Culminating in the release of AlphaFold 3 in 2024 1

   1

This progression has significantly enhanced the speed and precision of drug design, serving as the foundation for Isomorphic Labs' ambitious goals.

Source: Digit

Building a "World-Class Drug Design Engine"

Isomorphic Labs aims to revolutionize the pharmaceutical industry by:

1. Accelerating drug development processes
2. Reducing costs associated with drug discovery
3. Improving the success rate of drug candidates 3

   3

The company has made significant strides in achieving these objectives:

• Signed major research collaborations with Novartis and Eli Lilly in 2024
• Raised $600 million in external funding in April 2025, led by Thrive Capital 1

  1

AI-Powered Drug Discovery: A New Frontier

Traditional drug development is often a lengthy, expensive process with a high failure rate. Isomorphic Labs believes its AI-driven approach can dramatically improve these odds. The company is developing its own internal drug candidates in areas such as oncology and immunology, with plans to license them out after early-stage trials 4

4

Murdoch envisions a future where researchers can input a disease and have an AI system design an appropriate drug at the click of a button 1

1

Related Stories

Google DeepMind CEO Predicts AI-Designed Drugs in Clinical Trials by 2025

Alphabet's AI Drug Discovery Spin-off Isomorphic Labs Secures $600M in Landmark Funding Round

Google DeepMind and BioNTech Join Forces to Revolutionize Scientific Research with AI Lab Assistants

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Discovery and Advance Clinical Trials

The Competitive Landscape

As Isomorphic Labs prepares for human trials, other players in the field are also making significant progress:

• Recursion Pharmaceuticals expects seven programs to begin or conclude human studies next year
• Insilico Medicine has reported positive results from trials of its AI-designed drug for inflammatory bowel disease
• AMD has invested $20 million in Absci to challenge Nvidia's BioNeMo platform in AI drug discovery 3

  3

Source: Fast Company

The Road Ahead

As Isomorphic Labs prepares for this crucial phase, the scientific community and investors alike are watching closely. The success of these trials could mark a turning point in drug development, potentially leading to faster, more efficient, and more successful creation of new medicines 2

2